Invokana Lawsuit Plaintiffs Gain Support From European Medicines Agency Side Effect Warnings

March 22, 2016 – – TheProductLawyers.com reports on public safety warnings recently issued by the European Medicines Agency (EMA) which seem to link Invokana and similar SGLT2 inhibitor class, new-generation, type-2 diabetes drugs to reports of more than 100 cases of patients who have developed diabetic ketoacidosis around the world. The EMA stated, “Although diabetic ketoacidosis is usually accompanied by high blood sugar levels, in a number of these reports, blood sugar levels were only moderately increased. These uncharacteristic blood levels could delay diagnosis and treatment.”

Diabetic ketoacidosis is a possibly life-threatening medical condition in which the body’s bloodstream develops too much toxic acid. If the condition goes untreated, it can cause patients to slip into comas or even die. It has been noted to develop in as little as 24 hours, and, because it is now being discovered without the warning sign of significantly elevated blood sugar levels, it can be difficult to diagnose.

The acid develops in the blood stream from the presence of ketones which are created when the body is unable to get sufficient glucose (or sugar) which is used to make energy. If this is insufficient, the body will begin to burn fat for energy instead, which produces ketones, and can lead to the development of toxic acid in the blood. Allegations from multiple lawsuits which have now been filed, as well as several FDA adverse event reports, have linked Invokana use to several concerning medical conditions, including ketoacidosis, heart attack, bone fractures, and kidney damage or outright failure.

SGLT2 inhibitor class drugs work by helping to balance glucose levels in type-2 diabetic patients by ridding the body of excess sugar via urination. While they do this, they rely greatly on the kidneys and can cause increased bacteria to be present in these areas because of the sugar. The U.S. Food and Drug Administration (FDA) recently released a safety warning requiring that Invokana manufacturer Janssen Pharmaceuticals change the labeling on the drug, after receiving multiple reports of patients who took Invokana and developed ketoacidosis. FDA adverse event reports show that these patients required hospitalization, and several also stated that they required dialysis due to the development of kidney failure. When kidneys are damaged, they are unable to be repaired.

The attorneys of Banville Law are now helping assist patients who have taken Invokana or other SGLT2 class inhibitor drugs and who suffered from medical problems. These individuals deserve to be provided with the ability to fully investigate all legal options. To better assist those who wish to pursue justice, Banville Law offers free Invokana consultations and sponsors an online resource website at TheProductLawyers.com designed to keep the public informed on the latest important drug news.

To request more information, or to ask questions concerning Invokana lawsuits, please contact the attorneys at Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008817